Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Improving quality of life in metastatic castration-resistant prostate cancer: the role of androgen receptor axis-targeted agents
1Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03601 Martin, Slovak Republic
2Department of Urology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03601 Martin, Slovak Republic
DOI: 10.22514/jomh.2023.049 Vol.19,Issue 7,July 2023 pp.1-7
Submitted: 20 January 2023 Accepted: 06 March 2023
Published: 30 July 2023
*Corresponding Author(s): Ján Kliment E-mail: jan.kliment1@uniba.sk
Androgen receptor axis-targeted agents (ARTAs), specifically enzalutamide and abiraterone acetate, have significantly extended the survival of men with metastatic castration-resistant prostate cancer (mCRPC), making them the standard of care for mCRPC. In addition, the impact of both drugs on the health-related quality of life (HRQoL) represents an important therapeutic objective of mCRPC patients. This article aimed to review clinical evidence of HRQoL in mCRPC men treated with abiraterone acetate and enzalutamide and identify their potential benefits and correlation with overall survival or disease progression based on a literature search of randomized clinical trials, studies from real clinical practice and professional guidelines up to October 2022. The synthesized evidence showed that HRQoL of both novel hormonal therapies (NHTs) was evaluated as a secondary endpoint in pivotal trials. The results revealed that these novel agents might improve the HRQoL of mCRPC patients. However, it was difficult to compare the results between trials due to inconsistencies in trial designs and instruments. Correlation tests showed a positive correlation with HRQoL and clinical efficacy outcomes. Patient perspective was assessed only in a few comparative trials. In conclusion, both abiraterone acetate and enzalutamide improved the HRQoL of mCRPC patients. Nevertheless, further research is warranted as there was a limited number of head-to-head trials directly comparing the overall effects of ARTAs for mCRPC.
Quality of life; Abiraterone; Enzalutamide; Castration-resistant prostate cancer
Monika Kuzma,Mária Breznická,Ján Kliment. Improving quality of life in metastatic castration-resistant prostate cancer: the role of androgen receptor axis-targeted agents. Journal of Men's Health. 2023. 19(7);1-7.
[1] Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology. 2012; 13: 983–992.
[2] Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology. 2015; 16: 152–160.
[3] Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England Journal of Medicine. 2012; 367:1187–1197.
[4] Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. The New England Journal of Medicine. 2014; 371: 424–433.
[5] Moul JW, Dawson N. Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature. Cancer Investigation. 2012; 30: 1–12.
[6] Victorson DE, Beaumont JL, Rosenbloom SK, Shevrin D, Cella D. Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN/FACT-P symptom index. Psycho-Oncology. 2011; 20: 977–983.
[7] Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the functional assessment of cancer therapy-prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value in Health. 2009; 12: 124–129.
[8] Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997; 50: 920–928.
[9] Fujimura T, Takahashi S, Kume H, Takeuchi T, Clinical Study Group of Tokyo University Affiliated Hospitals, Kitamura T, et al. Cancer-related pain and quality of life in prostate cancer patients: assessment using the functional assessment of prostate cancer therapy. International Journal of Urology. 2009; 16: 522–525.
[10] Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, et al. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. European Journal of Cancer. 2013; 49: 3648–3657.
[11] Sternberg CN, Molina A, North S, Mainwaring P, Fizazi K, Hao Y, et al. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Annals of Oncology. 2013; 24: 1017–1025.
[12] Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. The Lancet Oncology. 2012; 13: 1210–1217.
[13] Rathkopf DE, Smith MR, De Bono JS, Logothetis CJ, Shore ND, De Souza P, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). European Urology 2014; 66:815–825.
[14] Shore N, Basch E, Ryan CJ, Mulders P, Kheoh T, Fizazi K, et al. The impact of abiraterone acetate on patient-reported pain and functional status in chemotherapy-naive patients with progressive, metastatic castration-resistant prostate cancer-results from an updated analysis. The Journal of Urology. 2013; 189: e323.
[15] Cella D, Li S, Li T, Kheoh T, Todd M, Basch E. Repeated measures analysis of patient-reported outcomes in prostate cancer after abiraterone acetate. The Journal of Community and Supportive Oncology. 2016; 14: 148–154.
[16] Traina S, Li L, Johnson K, Ho KF, Molina A, Cella D, et al. Analysis of the temporal relationship between patient-reported outcomes (PROs) and overall survival (OS) and radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts). Journal of Clinical Oncology. 2016; 34: 240.
[17] Fizazi K, Scher HI, Miller K, Basch E, Sternberg CN, Cella D, et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. The Lancet Oncology. 2014; 15: 1147–1156.
[18] Loriot Y, Miller K, Sternberg CN, Fizazi K, De Bono JS, Chowdhury S, et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. The Lancet Oncology. 2015; 16: 509–521.
[19] Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung D, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. The Lancet Oncology. 2016; 17: 153–163.
[20] Heidenreich A, Chowdhury S, Klotz L, Siemens DR, Villers A, Ivanescu C, et al. Impact of enzalutamide compared with bicalutamide on quality of life in men with metastatic castration-resistant prostate cancer: additional analyses from the TERRAIN randomised clinical trial. European Urology. 2017; 71: 534–542.
[21] Miller K, Cella D, Phung D, Naidoo S, HolmstromO S, Ivanescu C, et al. Relationship between quality of life (QoL) and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy: results from the AFFIRM study. Journal of Clinical Oncology. 2016; 34: 5060.
[22] Thiery-Vuillemin A, Poulsen MH, Dourthe LM, Trepiakas R, Lagneau E, Pintus EP, et al. Six-month patient reported outcome (PRO) results from AQUARiUS, a prospective, observational, multicenter phase 4 study in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone acetate + prednisone (AAP) or enzalutamide (ENZ). Journal of Clinical Oncology. 2018; 36: 5058.
[23] Thiery-Vuillemin A, Poulsen MH, Lagneau E, Ploussard G, Birtle A, Dourthe LM, et al. Impact of abiraterone acetate plus prednisone or enzalutamide on patient-reported outcomes in patients with metastatic castration-resistant prostate cancer: final 12-mo analysis from the observational AQUARiUS study. European Urology. 2020; 77: 380–387.
[24] Khalaf DJ, Sunderland K, Eigl BJ, Kollmannsberger CK, Ivanov N, Finch DL, et al. Health-related quality of life for abiraterone plus prednisone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: results from a phase II randomized trial. European Urology. 2019; 75: 940–947.
[25] Parimi S, Eigl BJ, Sunderland K, Zulfiqar M, Finch DL, Oja CD, et al. Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2016; 34: 5059.
[26] Ternov KK, SØnksen J, Fode M, Lindberg H, Kistorp C, Bisbjerg R, et al. Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: a randomised clinical trial (HEAT). European Journal of Cancer. 2022; 171: 75–84.
[27] Shore ND, Saltzstein D, Sieber P, Mehlhaff B, Gervasi L, Phillips J, et al. Results of a real-world study of enzalutamide and abiraterone acetate with prednisone tolerability (REAAcT). Clinical Genitourinary Cancer. 2019; 17: 457–463.
[28] El-Amm J, Nassabein R, Aragon-Ching JB. Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives. Cancer Management and Research. 2017; 9: 299–306.
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Directory of Open Access Journals (DOAJ) DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.
SCImago The SCImago Journal & Country Rank is a publicly available portal that includes the journals and country scientific indicators developed from the information contained in the Scopus® database (Elsevier B.V.)
Publication Forum - JUFO (Federation of Finnish Learned Societies) Publication Forum is a classification of publication channels created by the Finnish scientific community to support the quality assessment of academic research.
Scopus: CiteScore 0.9 (2023) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.
Norwegian Register for Scientific Journals, Series and Publishers Search for publication channels (journals, series and publishers) in the Norwegian Register for Scientific Journals, Series and Publishers to see if they are considered as scientific. (https://kanalregister.hkdir.no/publiseringskanaler/Forside).
Top